Aligos reports positive data from Phase IIa MASH treatment trial
In the trial, doses ranging from 0.5mg to 0.9mg of ALG-055009 led to notable median relative reductions in liver fat.
In the trial, doses ranging from 0.5mg to 0.9mg of ALG-055009 led to notable median relative reductions in liver fat.
The CAVA study is expected to validate the use of SmartPatch technology.
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms,...
Testosterone could influence men’s immune response to Covid-19
AstraZeneca eyes up transition to eco-friendly inhaler propellant
As mpox spreads, ‘national governments have a moral responsibility to help’
Ultromics’s EchoGo misses primary endpoint in heart disease trial